Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 2
1973 2
1976 3
1977 3
1978 9
1979 3
1980 8
1981 8
1982 2
1983 2
1984 1
1985 4
1986 2
1987 7
1988 8
1989 9
1990 8
1991 8
1992 4
1993 5
1995 4
1996 8
1997 5
1998 11
1999 9
2000 19
2001 15
2002 9
2003 19
2004 24
2005 27
2006 29
2007 43
2008 40
2009 38
2010 28
2011 28
2012 26
2013 23
2014 20
2015 20
2016 11
2017 9
2018 8
2019 16
2020 6
2021 5
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

568 results

Results by year

Filters applied: . Clear all
Page 1
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C; UNIFI Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750. N Engl J Med. 2019. PMID: 31553833 Free article. Clinical Trial.
[Gastritis and gastropathy].
Mihály E, Micsik T, Juhász M, Herszényi L, Tulassay Z. Mihály E, et al. Among authors: tulassay z. Orv Hetil. 2014 Jan 12;155(2):43-61. doi: 10.1556/OH.2014.29807. Orv Hetil. 2014. PMID: 24389321 Review. Hungarian.
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.
Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group. Feagan BG, et al. Among authors: tulassay z. N Engl J Med. 2016 Nov 17;375(20):1946-1960. doi: 10.1056/NEJMoa1602773. N Engl J Med. 2016. PMID: 27959607 Free article. Clinical Trial.
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.
Vermeire S, Sands BE, Tilg H, Tulassay Z, Kempinski R, Danese S, Bunganič I, Nitcheu J, Santo J, Scherrer D, Biguenet S, Ehrlich HJ, Steens JM, Gineste P, Sandborn WJ. Vermeire S, et al. Among authors: tulassay z. Lancet Gastroenterol Hepatol. 2022 Nov;7(11):1024-1035. doi: 10.1016/S2468-1253(22)00233-3. Epub 2022 Sep 6. Lancet Gastroenterol Hepatol. 2022. PMID: 36075249 Clinical Trial.
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
Octreotide.
Tulassay Z, Flautner L, Fehérvári I. Tulassay Z, et al. Lancet. 1992 Jun 6;339(8806):1428. doi: 10.1016/0140-6736(92)91259-b. Lancet. 1992. PMID: 1350848 No abstract available.
Controversials of Microscopic Colitis.
Mihaly E, Patai Á, Tulassay Z. Mihaly E, et al. Among authors: tulassay z. Front Med (Lausanne). 2021 Oct 12;8:717438. doi: 10.3389/fmed.2021.717438. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34712675 Free PMC article. Review.
Microscopic Colitis: A Challenging Disorder.
Tulassay Z, Mihaly E, Herszényi L. Tulassay Z, et al. Dig Dis. 2020;38(2):117-121. doi: 10.1159/000505263. Epub 2019 Dec 19. Dig Dis. 2020. PMID: 31865352 Free article. Review.
[Carcinoid tumors].
Pregun I, Bodoky G, Rácz K, Tulassay Z. Pregun I, et al. Among authors: tulassay z. Orv Hetil. 2010 Nov 14;151(46):1885-94. doi: 10.1556/OH.2010.29000. Orv Hetil. 2010. PMID: 21044939 Review. Hungarian.
568 results